Kisqali 600mg Tablet

Kisqali 600mg Tablet can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.    

Common side effects include:

• Infection
• Anemia
• Decreased appetite
• Vomiting
• Headache
• Low blood platelets
• Decreased potassium level in blood
• Decreased white blood cell count
• Dizziness
• Vertigo
• Fainting
• Increased lacrimation
• Breathlessness
• Cough
• Itching
• Abnormal liver enzyme
• Rash
• Nausea
• Constipation
• Fatigue
• Diarrhea
• Decreased white blood cell count
• Hair loss

• Take Kisqali 600mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• Ribociclib 600mg should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.
  

Kisqali 600mg Tablet contain active ingredient Ribociclib. It is a targeted therapy anticancer drug that works by blocking the action of proteins (kinases) which are responsible for the growth and division of cells. Results in slows the growth of cancer cells and eventually kills them.

• Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., ... & Jerusalem, G. (2020). Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New England Journal of medicine, 382(6), 514-524. https://pubmed.ncbi.nlm.nih.gov/31826360/
• Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., ... & Hortobagyi, G. (2024). Ribociclib plus endocrine therapy in early breast cancer. New England Journal of Medicine, 390(12), 1080-1091. https://pubmed.ncbi.nlm.nih.gov/38507751/
• Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., ... & Tripathy, D. (2019). Overall survival with ribociclib plus endocrine therapy in breast cancer. New England journal of medicine, 381(4), 307-316. https://www.nejm.org/doi/full/10.1056/NEJMoa1903765
• Tripathy, D., Bardia, A., & Sellers, W. R. (2017). Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clinical Cancer Research, 23(13), 3251-3262. https://pubmed.ncbi.nlm.nih.gov/28351928/
• Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., ... & O’Shaughnessy, J. (2016). Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England journal of medicine, 375(18), 1738-1748. https://www.nejm.org/doi/full/10.1056/NEJMoa1609709